Navigation Links
Cynosure Reports Record Revenues for Fourth-Quarter and Full-Year 2012
Date:2/12/2013

gation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including levels of demand for procedures performed with Cynosure products and for Cynosure products themselves, Cynosure's ability to maintain its profitability, competition in the aesthetic laser industry, general business and economic conditions, effects of acquisitions that Cynosure has made or may make, Cynosure's ability to develop and commercialize new products, Cynosure's reliance on sole source suppliers, the inability to accurately predict the timing or outcome of regulatory decisions, and economic, market, technological and other factors discussed in Cynosure's most recent Quarterly Report on Form 10-Q, which is filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Cynosure's views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, although Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release.Timothy BakerScott SolomonExecutive VP, Treasurer and CFOVice President Cynosure, Inc. Sharon Merrill 978.256.4200617.542.5300TBaker@cynosure.comCYNO@investorrelations.com Consolidated Statements of Income (Unaudited)(In thousands, except per share data)Three Months Ended December 31,Year Ended December 31,2012201120122011Revenues$
42,669

$
34,102$
53,493

$
,602Cost of revenues 17,878

14,91564,567

48,294Gross profit24,791

19,18788,926

62
'/>"/>

SOURCE Cynosure, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cynosure Receives FDA Clearance for At-Home Device for the Treatment of Wrinkles
2. Cynosure Announces Upcoming Conference Presentations
3. Cynosure, Inc. Announces Proposed Public Offering of Class A Common Stock
4. Cynosure, Inc. Prices Public Offering of Class A Common Stock
5. Cynosure to Present at Canaccord Genuity Medical Technology & Diagnostics Forum
6. Cynosure to Host Fourth-Quarter 2012 Financial Results Conference Call on February 12
7. Cynosure to Participate in Leerink Swann Global Healthcare Conference 2013
8. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
9. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
10. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
11. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... PRINCETON, N.J. , Aug. 31, 2015  /PRNewswire/ ... Company), a late-stage biopharmaceutical company developing products that ... inflammation, oncology and biodefense, announced today it has ... by the Data Review Committee (DRC) earlier this ... SGX942.  SGX942 is a first-in-class innate defense regulator ...
(Date:8/31/2015)... , Aug. 31, 2015  Asterias Biotherapeutics, ... on the emerging field of regenerative medicine, today ... at Chicago -based Rush University ... evaluating activity of escalating doses of AST-OPC1 (oligodendrocyte ... and motor complete cervical spinal cord injury (SCI). ...
(Date:8/31/2015)... and STAMFORD, Conn. , Aug. ... of Eisai Co., Ltd., and Purdue Pharma L.P. announced ... agreement for the development and commercialization of Eisai,s clinical ... antagonist entering Phase III clinical development for the treatment ... the agreement, Eisai and Purdue Pharma will share the ...
Breaking Medicine Technology:Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5
... 2011 Reportlinker.com announces that a ... in its catalogue: ... pricing rules set to negatively impact ... http://www.reportlinker.com/p0360217/Germany-Pharmaceutical-Market-Overview-–-New-pricing-rules-set-to-negatively-impact-drug-sales-both-domestically-and-internationally.html ...
... Ill., Jan. 11, 2011 Siemens Healthcare ... first competency-based clinical laboratory education model focused exclusively ... own instructional Avatar, are easily able to plan ... job-relevant courses. And because PEP also tracks each ...
Cached Medicine Technology:Reportlinker Adds Germany Pharmaceutical Market Overview - New pricing rules set to negatively impact drug sales both domestically and internationally 2Siemens Launches PEP, a Personalized Education Plan for Clinical Laboratory and Healthcare Professionals 2Siemens Launches PEP, a Personalized Education Plan for Clinical Laboratory and Healthcare Professionals 3
(Date:8/31/2015)... ... August 31, 2015 , ... Chicago-based company The Mood Factory, ... raise money and awareness for breast and ovarian health. During September and ... Mood-lite sold to Bright Pink® to encourage households, dorms, and offices around the ...
(Date:8/31/2015)... ... August 31, 2015 , ... Juvent Sports ( http://www.juvent.com ) just announced ... figures who are finding joint pain relief after using their revolutionary Micro-Impact Platform™ . ... in the world said, “For the first time in over 20 years I am ...
(Date:8/31/2015)... ... August 31, 2015 , ... Now here’s some good health ... "make at least half your grains whole,” with the majority of Americans eating more ... Whole Grains Council (WGC) released these findings and others from the 2015 Whole ...
(Date:8/31/2015)... ... August 31, 2015 , ... On Saturday, July 11, 2015, during ... in New York City, NYSATA was proud to recognize Dr. Merritt F. Spear as ... Recognition Award, named after long-time NYSATA member and Ithaca College athletic trainer and ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... All birth ... has one of the lowest failure rates among birth control methods. Moreover, no-scalpel vasectomy ... Still, some men hesitate to have their vasectomy done because they are afraid of ...
Breaking Medicine News(10 mins):Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 2Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 3Health News:Mats Wilander, 7 Grand Slam Title Winner and Tennis Legend, Now Plays Without Joint Pain 2Health News:Mats Wilander, 7 Grand Slam Title Winner and Tennis Legend, Now Plays Without Joint Pain 3Health News:Most Americans Now Make Half Their Grains Whole 2Health News:Most Americans Now Make Half Their Grains Whole 3Health News:Most Americans Now Make Half Their Grains Whole 4Health News:Most Americans Now Make Half Their Grains Whole 5Health News:NYS Athletic Trainers' Association Presents Recognition Awards at Annual Conference 2Health News:NYS Athletic Trainers' Association Presents Recognition Awards at Annual Conference 3Health News:One Stop Medical Center of Twin Cities Achieves Zero Failure Rate and Infection Rate in No Scalpel Vasectomy 2
... SILVER SPRING, Md., July 6 The Obesity Society, the ... obesity, is pleased to announce the selection of Francesca M. ... Ms. Dea comes to The Obesity Society with an ... and media relations. , , According to Robert Kushner, ...
... famotidine effective at curtailing ulcers , MONDAY, July 6 (HealthDay ... in people taking low-dose aspirin, often to reduce the risk ... phase III trial included 404 patients taking 75 milligrams to ... to take either 20 milligrams of famotidine or a placebo ...
... in those with advanced chronic heart failure, have an ... to new research from researchers at the University of ... in the European Heart Journal , also suggest ... risk of death in heart failure patients, contradicting previous ...
... 6 SCAN Health Plan of Arizona has announced that ... Studios today. This partnership allows SCAN Health Plan to regularly ... and weekend shows. , , SCAN also will serve ... Gila River Casino Club 55+. This initiative is part of ...
... future of organ transplantation could include microscopic beads that ... new organ, Medical College of Georgia researchers say. ... at the MCG Center for Molecular Chaperone/Radiobiology and Cancer ... with skin grafts. The degradable microparticles deliver the ...
... Blood Types - Patients Need YOU , , NEW ... York Blood Center (NYBC) and its divisions in Manhattan, Long ... call upon the community to please give blood this month. ... of all blood types and ethnicities are encouraged to donate ...
Cached Medicine News:Health News:The Obesity Society Selects Executive Vice President 2Health News:Drug Limits Stomach Trouble in Patients Taking Low-Dose Aspirin 2Health News:Atrial fibrillation linked to increased hospitalization in heart failure patients 2Health News:Arizona's AM 1230 KOY to be Broadcast from SCAN Health Plan Studios 2Health News:Microscopic 'beads' could help create 'designer' immune cells that ignore transplanted organs 2Health News:Who Says Negatives Can't Be Positive? 2Health News:Who Says Negatives Can't Be Positive? 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: